Search
01/08/2025
48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial
de Lazzari, E, Di Gregorio, S, Rojas, J, Curran, A, Domingo, P, Negredo, E, Tiraboschi, J, Gonzalez-Cordon, A, Torres, B, Sempere, A, Inciarte, A, Gatell, JM, Blanco, JL, Martinez, E. 48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2025; 80(8)DOI:10.1093/jac/dkaf192. PMID:40556520. IF:3.600(Q2/3D).
01/08/2025
A randomized study of 2 risk assessment models for individualized breast cancer risk estimation
López-Fernández, A, Duran-Lozano, L, Villacampa, G, Pardo, M, Pérez, E, Darder, E, Vallmajó, A, Alfonso, R, Cruellas, M, Roqué, A, Cartró, M, Bareas, A, Carrasco, E, Rezqallah, A, Jimenez-Macedo, AR, Torres-Esquius, S, Torres, M, Lopez, C, Espinosa, M, Teulé, A, Munté, E, Tuset, N, Diez, O, Feliubadaló, L, Lázaro, C, Llort, G, Carver, T, Ficorella, L, Mavaddat, N, Mercadé, A, Antoniou, AC, Brunet, J, Cajal, TRY, Balmaña, J. A randomized study of 2 risk assessment models for individualized breast cancer risk estimation. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2025; 117(8)DOI:10.1093/jnci/djaf067. PMID:40170233. IF:7.200(Q1/2D).
01/08/2025
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
van der Heijden, MS, Powles, T, Gupta, S, Loriot, Y, Galsky, MD, Valderrama, BP, Sridhar, SS, Yu, EY, Iyer, G, Kikuchi, E, Castellano, D, Hoffman-Censits, J, Drakaki, A, Mar, N, Rey, JPM, Vulsteke, C, Arafat, W, Duran, I, Dawson, NA, Swami, U, Gorla, S, Moreno, BH, Yu, X, Lu, YT, Bedke, J. Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. ESMO Open. 2025; 10(8)DOI:10.1016/j.esmoop.2025.105544. PMID:40795788. IF:8.300(Q1/2D).
01/08/2025
Primary Visceral Ewing Sarcoma (Gastric and Bladder) with KIT Expression: A Report of Two Patients and a Differential Diagnostic Approach
Chaachou-Charradi, A, Bagué, S, Medina, CM, Lavernia, J, Claramunt, R, Guerrero, JAL, Navarro, S, Llombart-Bosch, A, Williamson, SR, Machado, I. Primary Visceral Ewing Sarcoma (Gastric and Bladder) with KIT Expression: A Report of Two Patients and a Differential Diagnostic Approach. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY. 2025; 33(5)DOI:10.1177/10668969241308205. PMID:39865727. IF:1.000(Q3/8D).